In light of the 2012 fungal meningitis outbreak, believed to have been caused by a contaminated compounded steroid injection, the regulation of human drug compounding has received significant attention. Drug compounding in its traditional form is the process of combining, mixing, or altering ingredients in order to create a medication for a particular patient. However, as illustrated by the entity that created the steroid medication linked with the meningitis outbreak, concerns have been raised about compounding pharmacies producing drugs on a larger scale. While drug compounding has historically been the focus of state governments through their regulation of pharmacies, questions have arisen regarding the extent the federal government can regulate the practice of compounding through the Food, Drug, and Cosmetic Act (FDCA). This book examines the FDAs regulation of drug compounding and discusses relevant legal authorities, and the potential limits to the FDAs authority to regulate human drug compounding.
Preface; Federal Authority to Regulate the Compounding of Human Drugs; FDAs Authority to Regulate Drug Compounding:: A Legal Analysis; State of Disarray:: How States Inability to Oversee Compounding Pharmacies Puts Public Health at Risk; Compounding Pharmacies, Compounding Risk; The New England Compounding Center & the Meningitis Outbreak of 2012:: A Failure to Address Risk to the Public Health; Selected Resources on Federal Oversight of Compounding Pharmacies; Index.
Comments (0)
Your review appreciation cannot be sent
Report comment
Are you sure that you want to report this comment?
Report sent
Your report has been submitted and will be considered by a moderator.
Delivery policy
Security policy
Return policy
